Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

Psilocybin - a strategy of rapid antidepressant response in depression comorbid with cancer, a randomized double-blind study with the possibility of entering open extension.

To see complete record on, please visit this link

Id: 2020-005037-32

Organisation Name: Národní ústav duševního zdraví

Start Date: 2021-09-07

Completion Date: Ongoing

Brief Summary: The purpose of CT is to expand current therapeutic options for depression that accompanies cancer. The main potential benefit is a significant reduction in the mental suffering of these patients. It also compares the acute and long-term efficacy of two pharmacological experimental strategies of antidepressant response (psilocybin, ketamine).

Country: Czechia

Total execution time in seconds: 0.18571281433105